| 1. |
Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood, 2017, 129(21): 2836-2846.
|
| 2. |
张根生, 张淑芳, 王六红, 等. 血栓性血小板减少性紫癜合并急性心肌梗死一例. 中华医学杂志, 2006, 86(14): 1008.
|
| 3. |
Benhamou Y, Boelle P-Y, Baudin B, et al. Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the french thrombotic microangiopathies reference center. J Thromb Haemost, 2015, 13(2): 293-302.
|
| 4. |
Hughes C, McEwan JR, Longair I, et al. Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. J Thromb Haemost, 2009, 7(4): 529-536.
|
| 5. |
Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol, 2012, 158(3): 323-335.
|
| 6. |
Mariotte E, Azoulay E, Galicier L, et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol, 2016, 3(5): e237-e245.
|
| 7. |
George JN. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol, 2003, 10(5): 339-344.
|
| 8. |
Roriz M, Landais M, Desprez J, et al. Risk factors for autoimmune diseases development after thrombotic thrombocytopenic purpura. Medicine (Baltimore), 2015, 94(42): e1598.
|
| 9. |
Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum, 1992, 35(6): 630-640.
|
| 10. |
Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med, 2009, 361(17): 1676-1687.
|
| 11. |
Réti M, Farkas P, Csuka D, et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost, 2012, 10(5): 791-798.
|
| 12. |
Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol, 2012, 8(11): 622-633.
|
| 13. |
Mariette X, Criswell LA. Primary sjogren's syndrome. N Engl J Med, 2018, 378(10): 931-939.
|
| 14. |
Nocturne G, Mariette X. B cells in the pathogenesis of primary sjögren syndrome. Nat Rev Rheumatol, 2018, 14(3): 133-145.
|
| 15. |
Hovinga JAK, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2010, 115(8): 1500-1511.
|
| 16. |
Atteritano M, David A, Bagnato G, et al. Haemophagocytic syndrome in rheumatic patients. A systematic review. Eur Rev Med Pharmacol Sci, 2012, 16(10): 1414-1424.
|
| 17. |
Glennie MJ, French RR, Cragg MS, et al. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol, 2007, 44(16): 3823-3837.
|
| 18. |
Page EE, Kremer Hovinga JA, Terrell DR, et al. Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2016, 127(24): 3092-3094.
|
| 19. |
Theander E, Jonsson R, Sjöström B, et al. Prediction of sjögren's syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. Arthritis Rheumatol, 2015, 67(9): 2427-2436.
|
| 20. |
Brucato A, Cimaz R, Caporali R, et al. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clin Rev Allergy Immunol, 2011, 40(1): 27-41.
|
